Dateline City:
KENILWORTH, N.J.
Studies Published over the Last 10 Years Report Reductions in Cervical Pre-cancers and Other HPV-related Diseases
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
announced today that in a systematic review conducted of the global
impact and effectiveness of GARDASIL [Human Papillomavirus
Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], substantial
reductions were observed in HPV 6/11/16/18-related infection, genital
warts, Pap abnormalities and cervical pre-cancers.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Deb Wambold, 215-652-2913orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more